Turkey NPP Asset Scanner
254 molecules · EMA / FDA / EMA-only / FDA-only / TR Registered + YDIL · 2018–2026 · 🤝 Combined network: 5,600 contacts (Mustafa + Ufuk)
Last audit: 2026-05-05 (FDA novel approvals through Apr 2026 + EMA CHMP through Dec 2025) · Next audit due: 2026-08-05 · v53
Drag to reorder · Toggle to show/hide
157NPP Assets
🎯 Pipeline Mode — Candidate pool under triage. Click → to commit a product to Action, or ✕ to drop it.
EMA + FDA approved EU EMA-only US FDA-only ★ PPN Partner ★★ 2025–2026 New Orphan designated
🔧 Data Tools · TR data quality: — of — verified Verification chip on every product's expanded view shows last TITCK source & date · PDF button works offline (uses browser print dialog when CDN unreachable)
Clinical
Commercial
TR YDIL Status: On YDIL — import without per-patient TİTCK approval ⭐Fast-track — no additional TİTCK written approval needed (Sheet 2) Individual application — 3-physician council + TİTCK review per patient New — not on YDIL; new TİTCK pathway required ✓ Verified against TİTCK YDIL Excel dated 28/04/2026
Products you've dropped from active pursuit. Click Restore to move back to Pipeline.
🧬 Gene & Cell Therapies — Different Access Pathway
In Turkey, gene therapies and cell therapies are categorically excluded from the YDIL (Yurtdışı İlaç Listesi). Standard NPP commercial routes do not apply. Access pathways for these products typically require: individual TİTCK applications, special patient programs, treatment-abroad referrals (yurtdışı tedavi), or direct Ministry of Health negotiation. BD positioning, pricing, and patient identification mechanics differ substantially from the standard NPP model — these belong in a dedicated workstream.